• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Novo - The leader in Diabetes Care

anonymous

Guest
Oral semaglutide is just around the corner!!! Is anyone else nervous about this approval?? Why is Novo ALWAYS ahead of Lilly in approvals of new therapies? Their new insulin pen devices are coming out before ours as well! Anything new has really come from BI. Of course Trulicity is ours but before that it was Humalog in 1998. Why is it that our Lilly scientists can’t come up with anything new? Nasal glucagon might be new but it’s not going to help but a few Type 1’s.
 

<



Maybe because we take long lunch breaks.
Yours truly,
R&D scientist

Oral semaglutide is just around the corner!!! Is anyone else nervous about this approval?? Why is Novo ALWAYS ahead of Lilly in approvals of new therapies? Their new insulin pen devices are coming out before ours as well! Anything new has really come from BI. Of course Trulicity is ours but before that it was Humalog in 1998. Why is it that our Lilly scientists can’t come up with anything new? Nasal glucagon might be new but it’s not going to help but a few Type 1’s.
 




Maybe because we take long lunch breaks.
Yours truly,
R&D scientist

You really have no clue as to LRL's issues ... the bench scientists are not the problem.

It's the PhD's, who haven't gone anywhere near the bench in YEARS; and couldn't run an experiment to save their lives. Too busy filling up their daily calendar with worthless meeting and networking opportunities.
 




You really have no clue as to LRL's issues ... the bench scientists are not the problem.

It's the PhD's, who haven't gone anywhere near the bench in YEARS; and couldn't run an experiment to save their lives. Too busy filling up their daily calendar with worthless meeting and networking opportunities.

The problem is HR. They tell scientists to GET RESULTS THROUGH OTHERS which is a pathetic, manipulative, lackadaisical and dysfunctional approach. HR should be shaken up- new blood, new ideas please!
 




Let the scientists do their thing and stop interfering with the initiative of the month, reorganizing, laying off staff.
This is the result of years led by managers who do not understand what it takes to discover new medicines.

Eli Lilly misses estimates 1Q 19



The problem is HR. They tell scientists to GET RESULTS THROUGH OTHERS which is a pathetic, manipulative, lackadaisical and dysfunctional approach. HR should be shaken up- new blood, new ideas please!
 




yeah, let them focus on their six sigma projects and all will be well.

Senior managers in Lilly scientific groups allowed a lot of crap like sigma to creep into their departments, just to please higher executives. They were focussed on their own career path and not doing what's best for long term company growth. Truth is, R&D is fuc*ed and it won't just miraculously start working again once you clear the BS away. Too much damage because the best scientists are gone along with the collaborative spirit. Leftovers are just collecting a paycheck until retirement.

Let the scientists do their thing and stop interfering with the initiative of the month, reorganizing, laying off staff.
This is the result of years led by managers who do not understand what it takes to discover new medicines.

Eli Lilly misses estimates 1Q 19
 








How can Novo be beat when REWIND missed expectations

Oral semaglutide is just around the corner!!! Is anyone else nervous about this approval?? Why is Novo ALWAYS ahead of Lilly in approvals of new therapies? Their new insulin pen devices are coming out before ours as well! Anything new has really come from BI. Of course Trulicity is ours but before that it was Humalog in 1998. Why is it that our Lilly scientists can’t come up with anything new? Nasal glucagon might be new but it’s not going to help but a few Type 1’s.
 




Similar threads